ABSTRACT: Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality in solid organ transplantation. Disseminated toxoplasmosis after liver transplantation is a rare but fatal event. Serologic screening of the donor and the recipient is essential to prophylactic management, early diagnosis and therapeutic strategies to minimize the consequences of these infections. The aim of the present study was to determine the seroprevalence of CMV and Toxoplasma gondii (TG) in a Brazilian liver transplant waiting list (LTWL). Serological data were collected from 44 candidates on the LTWL between May 2003 and November 2004. Serological investigation of antibodies IgM and IgG against CMV (anti-CMV) and TG (anti-T. gondii) was performed using fluorometry commercial kits. IgG anti-CMV was positive in 37 patients (94.9%) out of 39 available results. There were not IgM anti-CMV positive results. Out of 36 analyzed patients, 22 (61.1%) presented positive IgG anti-T. gondii and none had positive IgM anti-T. gondii. The high CMV seroprevalence among our LTWL reinforces the need for appropriate protocols to avoid related complications, like reactivation and superinfection by CMV. Environmental and drug prophylactic strategies against primary infection and reactivation, as well as early diagnosis and treatment of toxoplasmosis complications, are essential for the good outcome of transplant patients.
INTRODUCTION
Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality in solid organ transplantation. It is also associated with an increased risk of opportunistic infections, allograft injury and also seems to increase the risk of acute and chronic allograft rejection (6) . Disseminated toxoplasmosis after liver transplantation is a rare event but in most cases results in a fatal outcome (4) . CMV and Toxoplasma gondii (TG) infection complications have been due to primary infection or superinfection from a latently infected donor organ or to reactivation of latent organisms in a seropositive recipient. CMV can also be acquired from blood products (8, 9) .
Serologic screening of donor and recipient, previous to the transplant, is essential to prophylactic management, early diagnosis and therapeutic strategies to minimize the consequences of these infections (11) . The aim of this study was to determine the seroprevalence of CMV and TG among our liver transplant waiting list (LTWL). Table 1 .
The high CMV seroprevalence among our LTWL was similar to that observed in Brazilian community (1). Seroprevalence was higher than in developed countries, which is probably related to the socioeconomic milieu (7, 12 
